4-cyclohexylphthalazin-1(2H)-one | 19487-16-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-cyclohexylphthalazin-1(2H)-one
• 英文别名: 4-Cyclohexyl-phthalazon-(1)；4-cyclohexyl-2H-phthalazin-1-one；4-cyclohexyl-1-phthalazinone；4-cyclohexyl-2H-phthalazin-1-one
• CAS: 19487-16-2
• 化学式: C₁₄H₁₆N₂O
• 分子量: 228.294
• InChiKey: ZUILAXWRCONLKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-cyclohexylphthalazin-1(2H)-one 在 三氯氧磷 作用下， 反应 18.0h， 以96%的产率得到1-chloro-4-cyclohexylphthalazine
  参考文献：
  名称：

  通过3-取代的3-羟基异吲哚啉-1-酮合成4-取代的氯邻苯二甲酰肼，二氢苯并氮杂氮杂二酮，2-吡唑基苯甲酸和2-吡唑基苯甲酰肼

  摘要：

  在本文中，我们描述了以良好的总收率进行的4-取代的氯邻苯二甲腈的一般三步合成。在关键步骤中，N，N-二甲基氨基邻苯二甲酰亚胺（8a）指导烷基，芳基和杂芳基有机金属试剂的选择性单加成反应，得到3-取代的3-羟基异吲哚满酮9b，9i - 9am。通过与肼反应，然后用POCl 3氯化，许多羟基异吲哚啉酮可转化为氯酞嗪1b - 1v。我们还发现了3-乙烯基和3-炔基-3-羟基异吲哚满酮的两个新颖的转化。将乙烯基有机金属试剂添加到N，N-二甲基氨基邻苯二甲酰亚胺（8a）通过提议的3-乙烯基-3-羟基异吲哚满酮中间体的扩环作用提供了二氢苯并氮杂氮杂二酮15a - 15c。3-炔基-3-羟基异吲哚啉酮与肼和取代的肼反应，生成2-吡唑基苯甲酸16a - 16d和2-吡唑基苯并酰肼17a - 17g，而不是预期的炔基酞菁。

  DOI：

  10.1021/jo3000628
• 作为产物：
  描述：

  环己氯化镁 在 一水合肼 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 5.5h， 生成 4-cyclohexylphthalazin-1(2H)-one
  参考文献：
  名称：

  Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones

  摘要：

  A number of 4-substituted 2-[omega-(1-imidazolyl)allryl]-1(2H)-phthalazinones were synthesized in order to develop agents possessing both thromboxane Az synthetase inhibitory and bronchodilatory activities. The pharmacological evaluation of these compounds disclosed that they have both activities to various extents. Both activities were slightly dependent on the length of the 2-substituents and largely affected by the nature of the 4-substituents. Compounds bearing phenyl and thienyl groups exhibited relatively high and well-rounded activities. Among these compounds, 12j and 15f were found to be the most effective agents having well-rounded activities in vitro and in vivo. Introduction of a carboxyl group reduced both activities contrary to our expectation. 4-(3-Pyridyl)phthalazinone 18b was of particular interest because of unexpectedly high in vivo activities in spite of an absence of significant in vitro activities.

  DOI：

  10.1021/jm00077a008

文献信息

• POTASSIUM CHANNEL MODULATORS
  申请人：Brown Brian S.

  公开号：US20110124642A1

  公开（公告）日：2011-05-26

  Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein ring Z 1 , R 1 , p, R 3 , and R 4 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

  本文披露了具有以下结构的KCNQ钾通道调节剂（I）： 其中环Z 1 ，R 1 ，p，R 3 和R 4 如规范中所定义。还描述了包含这些化合物的组合物；以及使用这些化合物和组合物治疗疾病和疾病的方法。
• Palladium-Catalyzed Acylation Reactions: A One-Pot Diversified Synthesis of Phthalazines, Phthalazinones and Benzoxazinones
  作者：Basuli Suchand、Gedu Satyanarayana

  DOI：10.1002/ejoc.201800159

  日期：2018.5.24

  proceeds through [Pd]‐catalyzed acylation and nucleophilic cyclocondensation with dinucleophilic reagents. This process was based on direct coupling with simple bench‐top aldehydes without the assistance of directing group and without activating the carbonyl group. The process is highly advantageous because it employs simple nitrogen‐based nucleophiles, and non‐toxic and readily accessible aldehydes as the

  提出了一种用于酞嗪、酞嗪酮和苯并恶嗪酮多样化合成的连续单锅策略。该策略通过 [Pd] 催化的酰化和与双亲核试剂的亲核环缩合反应进行。该过程基于与简单的台式醛直接偶联，没有导向基团的帮助，也没有活化羰基。该方法非常有利，因为它使用简单的氮基亲核试剂和无毒且易于获得的醛作为羰基来源。最重要的是，该策略被应用于 PDE-4 抑制剂的一锅合成。
• 3,6-disubstituted pyradazine derivatives
  申请人：Mitsubishi Chemical Corporation

  公开号：US05462941A1

  公开（公告）日：1995-10-31

  A 3,6-disubstituted pyridazine derivative having excellent platelet agglutination inhibitory effects. It is useful for a preventive medicine or a therapeutic medicine for a cerebrovascular disorder such as cerebral thrombosis and cerebral embolism, an ischemic heart disease such as myocardial infarction, and a circulation disorder such as peripheral circulation disorder. A pharmaceutical composition containing a compound of the present invention as an effective ingredient and a process for preparing the same are also disclosed. The compound has the formula (I) ##STR1## wherein A represents an alkyl group having 3 to 6 carbon atoms; a cycloalkyl group having 5 to 7 carbon atoms; a phenyl group, a thienyl group, a furyl group, a thiazolyl group, a phenoxy group, a phenylalkyl group having 7 to 9 carbon atoms, a phenylthio group, a 5-6 membered saturated heterocyclic group containing one or more nitrogen atoms, a pyridyl group or an imidazolyl group each of which may have at least one substituent selected from the group consisting of an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms and a halogen atom; B represents (a) --NH--D wherein D represents ##STR2## (4) --CH.sup.3 R.sup.4 ; or (5) an alkyl group having 3 to 8 carbon atoms; or ##STR3## and the ring C represents a benzene ring.

  一种具有出色的血小板凝聚抑制作用的3,6-二取代吡啶嗪衍生物。它可用于预防或治疗脑血栓和脑栓塞等脑血管疾病，心肌梗死等缺血性心脏病以及外周循环障碍等循环系统疾病的预防性或治疗性药物。本发明还公开了一种含有该化合物作为有效成分的制药组合物以及其制备方法。该化合物的化学式为（I）其中，A代表具有3到6个碳原子的烷基；具有5到7个碳原子的环烷基；苯基，噻吩基，呋喃基，噻唑基，苯氧基，具有7到9个碳原子的苯基烷基，苯硫基，含有一个或多个氮原子的5-6成员饱和杂环基，吡啶基或咪唑基，其中每个基团都可以具有至少一个选自由1到4个碳原子的烷基，1到4个碳原子的烷氧基和卤素原子的取代基；B代表（a）--NH--D，其中D代表##STR2##（4）--CH3R4；或（5）具有3到8个碳原子的烷基；或##STR3##环C代表苯环。
• Stop-Flow Microtubing Reactor-Assisted Visible Light-Induced Hydrogen-Evolution Cross Coupling of Heteroarenes with C(sp³)–H Bonds
  作者：Dong-Sheng Li、Tao Liu、Yang Hong、Chen-Lin Cao、Jie Wu、Hong-Ping Deng

  DOI：10.1021/acscatal.2c01087

  日期：2022.4.15

  feedstocks under mild conditions is attractive and highly desirable in pharmaceutical and natural product synthesis. Minisci-type cross dehydrogenative coupling between heteroarenes and C(sp3)–H bonds offers direct access to these important scaffolds in a step-economic manner. Herein, assisted by stop-flow microtubing reactors, an operationally simple protocol for the visible light-induced hydrogen-evolution

  在温和条件下从丰富且廉价的原料合成有价值的烷基取代的杂芳烃在药物和天然产物合成中具有吸引力和高度可取性。杂芳烃和 C(sp 3 )-H 键之间的 Minisci 型交叉脱氢偶联以逐步经济的方式提供了对这些重要支架的直接访问。在此，在停流微管反应器的辅助下，一种操作简单的协议，用于可见光诱导的杂芳烃与未活化 C(sp 3 ) 的析氢交叉耦合)–H 键以无金属和无外部氧化剂的方式形成。使用常见的原料化学品（包括乙烷）生成了范围广泛的烷基化杂芳烃。机理研究表明，光氧化还原诱导的氢原子转移过程，然后是脱氢重芳构化，提供了所需的偶联产物。各种复杂生物活性分子的后期功能化进一步证明了该策略的优点。
• PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
  申请人：FLATLEY DISCOVERY LAB

  公开号：US20150005300A1

  公开（公告）日：2015-01-01

  The invention relates to a compound of having the following formulae and methods of treating cystic fibrosis:

  本发明涉及一种具有以下化学式的化合物和治疗囊性纤维化的方法: